Lucid Diagnostics (LUCD)
Market Price (5/5/2026): $1.1 | Market Cap: $144.5 MilSector: Health Care | Industry: Life Sciences Tools & Services
Lucid Diagnostics (LUCD)
Market Price (5/5/2026): $1.1Market Cap: $144.5 MilSector: Health CareIndustry: Life Sciences Tools & Services
Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.
Megatrend and thematic driversMegatrends include Biotechnology & Genomics, and Precision Medicine. Themes include Advanced Diagnostics, and Personalized Diagnostics. | Weak multi-year price returns3Y Excs Rtn is -101% | Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -50 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -1055% Significant share based compensationSBC/Rev LTMShare Based Compensation / Revenue (Sales), Last Twelve Months (LTM) is 95% Not cash flow generativeCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -988%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -992% Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -45% Key risksLUCD key risks include [1] its precarious financial health and high bankruptcy risk, Show more. |
| Megatrend and thematic driversMegatrends include Biotechnology & Genomics, and Precision Medicine. Themes include Advanced Diagnostics, and Personalized Diagnostics. |
| Weak multi-year price returns3Y Excs Rtn is -101% |
| Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -50 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -1055% |
| Significant share based compensationSBC/Rev LTMShare Based Compensation / Revenue (Sales), Last Twelve Months (LTM) is 95% |
| Not cash flow generativeCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -988%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -992% |
| Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -45% |
| Key risksLUCD key risks include [1] its precarious financial health and high bankruptcy risk, Show more. |
Qualitative Assessment
AI Analysis | Feedback
1. Equity Offering and Dilution.
Lucid Diagnostics announced and closed an $18 million underwritten offering of 18,000,000 common shares priced at $1.00 per share on April 23-24, 2026. This significant equity raise, intended for working capital and general corporate purposes, likely contributed to dilution and put downward pressure on the stock price, as such capital-raising events historically coincide with share-price pressure.
2. Q4 2025 Earnings Per Share Miss.
On March 26, 2026, Lucid Diagnostics reported its fourth-quarter and full-year 2025 financial results. While the company's revenue of $1.5 million for Q4 2025 surpassed analyst expectations of $1.39 million, its earnings per share (EPS) of -$0.10 missed the consensus estimate of -$0.07. This continued unprofitability, despite revenue growth and increased test volumes, likely contributed to investor apprehension.
Show more
Stock Movement Drivers
Fundamental Drivers
The -8.4% change in LUCD stock from 1/31/2026 to 5/4/2026 was primarily driven by a -17.7% change in the company's Shares Outstanding (Mil).| (LTM values as of) | 1312026 | 5042026 | Change |
|---|---|---|---|
| Stock Price ($) | 1.19 | 1.09 | -8.4% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 4 | 5 | 7.0% |
| P/S Multiple | 29.3 | 30.4 | 4.0% |
| Shares Outstanding (Mil) | 108 | 131 | -17.7% |
| Cumulative Contribution | -8.4% |
Market Drivers
1/31/2026 to 5/4/2026| Return | Correlation | |
|---|---|---|
| LUCD | -8.4% | |
| Market (SPY) | 3.6% | 33.0% |
| Sector (XLV) | -6.1% | 33.9% |
Fundamental Drivers
The -9.9% change in LUCD stock from 10/31/2025 to 5/4/2026 was primarily driven by a -24.7% change in the company's Shares Outstanding (Mil).| (LTM values as of) | 10312025 | 5042026 | Change |
|---|---|---|---|
| Stock Price ($) | 1.21 | 1.09 | -9.9% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 4 | 5 | 7.9% |
| P/S Multiple | 27.5 | 30.4 | 10.8% |
| Shares Outstanding (Mil) | 99 | 131 | -24.7% |
| Cumulative Contribution | -9.9% |
Market Drivers
10/31/2025 to 5/4/2026| Return | Correlation | |
|---|---|---|
| LUCD | -9.9% | |
| Market (SPY) | 5.5% | 22.0% |
| Sector (XLV) | 1.2% | 23.4% |
Fundamental Drivers
The -12.8% change in LUCD stock from 4/30/2025 to 5/4/2026 was primarily driven by a -55.5% change in the company's Shares Outstanding (Mil).| (LTM values as of) | 4302025 | 5042026 | Change |
|---|---|---|---|
| Stock Price ($) | 1.25 | 1.09 | -12.8% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 4 | 5 | 8.3% |
| P/S Multiple | 16.8 | 30.4 | 81.1% |
| Shares Outstanding (Mil) | 58 | 131 | -55.5% |
| Cumulative Contribution | -12.8% |
Market Drivers
4/30/2025 to 5/4/2026| Return | Correlation | |
|---|---|---|
| LUCD | -12.8% | |
| Market (SPY) | 30.4% | 14.7% |
| Sector (XLV) | 4.9% | 12.1% |
Fundamental Drivers
The -25.9% change in LUCD stock from 4/30/2023 to 5/4/2026 was primarily driven by a -79.1% change in the company's P/S Multiple.| (LTM values as of) | 4302023 | 5042026 | Change |
|---|---|---|---|
| Stock Price ($) | 1.47 | 1.09 | -25.9% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 0 | 5 | 1148.3% |
| P/S Multiple | 145.8 | 30.4 | -79.1% |
| Shares Outstanding (Mil) | 37 | 131 | -71.5% |
| Cumulative Contribution | -25.9% |
Market Drivers
4/30/2023 to 5/4/2026| Return | Correlation | |
|---|---|---|
| LUCD | -25.9% | |
| Market (SPY) | 78.7% | 15.3% |
| Sector (XLV) | 13.9% | 12.0% |
Price Returns Compared
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| LUCD Return | -54% | -75% | 4% | -42% | 33% | 0% | -91% |
| Peers Return | -4% | -61% | 16% | 9% | 60% | -28% | -44% |
| S&P 500 Return | 27% | -19% | 24% | 23% | 16% | 6% | 92% |
Monthly Win Rates [3] | |||||||
| LUCD Win Rate | 0% | 33% | 67% | 42% | 58% | 60% | |
| Peers Win Rate | 42% | 30% | 50% | 42% | 52% | 40% | |
| S&P 500 Win Rate | 75% | 42% | 67% | 75% | 67% | 60% | |
Max Drawdowns [4] | |||||||
| LUCD Max Drawdown | -59% | -77% | -15% | -52% | -3% | -6% | |
| Peers Max Drawdown | -30% | -70% | -23% | -31% | -35% | -36% | |
| S&P 500 Max Drawdown | -1% | -25% | -1% | -2% | -15% | -7% | |
[1] Cumulative total returns since the beginning of 2021
[2] Peers: CSTL, GH, VCYT, NEO, FLGT.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 5/4/2026 (YTD)
How Low Can It Go
| Event | LUCD | S&P 500 |
|---|---|---|
| 2025 US Tariff Shock | ||
| % Loss | -31.4% | -18.8% |
| % Gain to Breakeven | 45.9% | 23.1% |
| Time to Breakeven | 37 days | 79 days |
| 2024 Yen Carry Trade Unwind | ||
| % Loss | -10.9% | -7.8% |
| % Gain to Breakeven | 12.2% | 8.5% |
| Time to Breakeven | 11 days | 18 days |
| Summer-Fall 2023 Five Percent Yield Shock | ||
| % Loss | -11.5% | -9.5% |
| % Gain to Breakeven | 12.9% | 10.5% |
| Time to Breakeven | 7 days | 24 days |
In The Past
Lucid Diagnostics's stock fell -31.4% during the 2025 US Tariff Shock. Such a loss loss requires a 45.9% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
| Event | LUCD | S&P 500 |
|---|---|---|
| 2025 US Tariff Shock | ||
| % Loss | -31.4% | -18.8% |
| % Gain to Breakeven | 45.9% | 23.1% |
| Time to Breakeven | 37 days | 79 days |
In The Past
Lucid Diagnostics's stock fell -31.4% during the 2025 US Tariff Shock. Such a loss loss requires a 45.9% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
About Lucid Diagnostics (LUCD)
AI Analysis | Feedback
Lucid Diagnostics (LUCD) is like:
- The **Exact Sciences** (maker of Cologuard) of esophageal cancer screening.
AI Analysis | Feedback
```html- EsoGuard: A laboratory developed esophageal DNA test for patients at risk of esophageal precancer and cancer.
- EsoCheck: An esophageal cell collection device used to collect cells for the EsoGuard test.
AI Analysis | Feedback
Lucid Diagnostics Inc. (LUCD) sells its medical diagnostic products and services primarily to healthcare providers and organizations, not directly to individuals. While the company's background description does not name specific major customer companies, the primary categories of its customers within the healthcare sector are:
-
Gastroenterology Clinics and Practices: These specialized medical practices are focused on diagnosing and treating disorders of the digestive system, including gastroesophageal reflux disease and esophageal conditions. They would be key users of EsoGuard and EsoCheck for patient screening and management.
-
Hospitals: Medical institutions providing comprehensive patient care, including diagnostic services and specialized departments like gastroenterology. Hospitals would integrate Lucid Diagnostics' products into their diagnostic pathways for at-risk patients.
-
Primary Care Physicians (PCPs) and Internal Medicine Practices: General practitioners and internal medicine doctors often manage patients with chronic heartburn and may be early referrers or direct users of screening tools like EsoGuard and EsoCheck for identifying patients at risk of esophageal precancer.
AI Analysis | Feedback
nullAI Analysis | Feedback
Lishan Aklog, M.D. Chairman & Chief Executive Officer
Dr. Aklog is the Chairman & CEO of Lucid Diagnostics and also co-founded PAVmed Inc., Lucid's parent company, where he also serves as Chairman & CEO. He previously co-founded a medtech holding company that established four medical device companies and led one of these portfolio companies that commercialized his invention, AngioVac®, which was subsequently sold. He has served as a consultant for leading medical technology companies and is an inventor on numerous patents. Before his career as an entrepreneur and executive, Dr. Aklog had a distinguished career as an innovator in cardiac surgery, holding faculty positions at Harvard Medical School and Mount Sinai Medical Center.
Dennis McGrath Chief Financial Officer
Mr. McGrath has served as Lucid Diagnostics' Executive Vice President and Chief Financial Officer since March 2017. Prior to joining Lucid, from 2000 to 2017, he held various senior-level positions at PhotoMedex, Inc., a global medical device company. These roles included director, President, and Chief Financial Officer from 2011 to 2017, and Chief Executive Officer from 2009 to 2011. He also served as Vice President of Finance and Chief Financial Officer at PhotoMedex from 2000 to 2009. He is responsible for Lucid's financial management, strategic financial planning, accounting, and investor relations. Mr. McGrath is a Certified Public Accountant and holds a Bachelor of Science degree in Accounting from the University of Kentucky.
Shaun O'Neil, MBA President & Chief Operating Officer
Mr. O'Neil has served as President & Chief Operating Officer of Lucid Diagnostics since November 2023, having previously been the company's Chief Commercial Officer. He is responsible for leading strategic initiatives at Lucid, including the development and launch of commercial operations, sales and marketing strategy, market access, and the management of Lucid Dx Labs, the company's CLIA-certified laboratory. Mr. O'Neil brings over two decades of experience in the medical technology sector.
Michael Gordon General Counsel & Corporate Secretary
Mr. Gordon serves as Lucid Diagnostics' General Counsel & Corporate Secretary.
Suman M. Verma, MD, PhD Chief Scientific Officer
Dr. Verma is the Chief Scientific Officer of Lucid Diagnostics. She also holds positions as Vice Chairman of Pathology, Clinical Affairs, and Laboratory Director at University Hospitals Cleveland Medical Center, and is a Professor in the Department of Pathology at Case Western Reserve University, School of Medicine. Her expertise in medical science and diagnostics research is crucial for shaping the company's scientific strategy, overseeing research initiatives, and ensuring the scientific integrity of Lucid Diagnostics' products.
AI Analysis | Feedback
The key risks to Lucid Diagnostics (LUCD) largely revolve around securing broad market acceptance and favorable reimbursement for its diagnostic products.
1. Reimbursement Uncertainty and Delays
The most significant risk for Lucid Diagnostics is the uncertainty and potential delays in securing broad Medicare and commercial payer coverage for its lead products, EsoGuard and EsoCheck. The company's revenue recognition is heavily reliant on cash collections from submitted claims, leading to a lag in recognizing near-term revenue. This challenging reimbursement environment can result in elongated collection times, and many claims may be denied or require further authorization. Delays in obtaining Medicare coverage, in particular, could significantly constrain revenue growth, as Medicare patients represent a substantial portion of the addressable population.
2. Significant Cash Burn and Need for Additional Funding
Lucid Diagnostics is currently an unprofitable, commercial-stage company experiencing a rapid cash burn. This necessitates ongoing efforts to raise additional capital, often through dilutive funding, which can be a concern for existing shareholders. Prolonged periods of low revenue due to reimbursement challenges could accelerate the cash burn rate, potentially making future fundraising more difficult or on less favorable terms.
3. Market Adoption Challenges
Lucid Diagnostics faces challenges in achieving widespread market adoption of its EsoGuard/EsoCheck tests. This includes potential slow clinician adoption and extended sales cycles, particularly when penetrating new markets such as concierge medicine or securing large direct contracts. Declines in test volumes could indicate difficulties in convincing healthcare providers and patients to adopt the tests, which may impact investor confidence and extend the timeline to profitability.
AI Analysis | Feedback
nullAI Analysis | Feedback
The addressable market for Lucid Diagnostics' lead products, EsoGuard and EsoCheck, is approximately $60 billion in the U.S.. This market size is based on an estimated 30 million at-risk patients with chronic gastroesophageal reflux disease (GERD).
AI Analysis | Feedback
Here are 3-5 expected drivers of future revenue growth for Lucid Diagnostics (LUCD) over the next 2-3 years:
- Expansion of Insurance Coverage, particularly Medicare: Lucid Diagnostics anticipates significant revenue growth from securing broader insurance coverage for its EsoGuard test, especially from Medicare. A favorable Medicare Local Coverage Determination (LCD) through the MolDX program, with a draft expected in late 2025 and a final decision likely in 2026, is seen as a pivotal milestone that could unlock a large market segment. The company is actively engaged in discussions with major commercial payors and had a MolDX pre-submission meeting scheduled for July 2024 to review data for technical assessment.
- Increased Adoption and Test Volumes of EsoGuard and EsoCheck: Consistent growth in the number of EsoGuard tests performed is a key driver. The company has demonstrated year-over-year increases in EsoGuard test volumes, reaching 2,841 tests in Q3 2025 and a record of 4,042 tests in Q4 2024, indicating solid demand for its diagnostic solutions. Management is focusing on revenue-driving activities, where increased test volumes are expected to translate into higher revenue.
- Launch and Growth of New Sales Channels: Lucid Diagnostics expects substantial revenue contributions from developing and expanding new sales channels. This includes the implementation of concierge medicine programs and direct contracting initiatives with employers and self-insured entities, with significant contributions anticipated starting in the second half of 2025. The company's "CYFT events" (targeting groups like firefighters) are also a thriving aspect of these direct contracting efforts.
- Strengthened Clinical Evidence and Guideline Inclusion: The continuous accumulation of strong clinical validity and utility data for EsoGuard is crucial for driving medical policy coverage and widespread adoption. The peer-reviewed publication of positive data from a National Cancer Institute (NCI)-sponsored clinical validation study, demonstrating "unprecedented early pre-cancer detection," enhances EsoGuard's credibility. Additionally, recent real-world data from nearly 12,000 patients further confirms the safety, tolerability, and scalability of EsoCheck and EsoGuard in routine clinical practice, supporting its utility as a non-invasive screening tool. Inclusion in NCCN (National Comprehensive Cancer Network) guidelines is also expected to bolster credibility and support revenue growth.
AI Analysis | Feedback
Share Issuance
- Lucid Diagnostics completed its Initial Public Offering (IPO) in October 2021, selling 5,000,000 shares of common stock at $14.00 per share, resulting in gross proceeds of $70,000,000.
- In September 2025, the company closed an underwritten public offering of 28,750,000 shares of common stock at $1.00 per share, yielding approximately $26.9 million in net proceeds.
- Prior to terminating its At-The-Market (ATM) Prospectus Supplement in March 2025, Lucid Diagnostics sold 230,068 shares for an aggregate purchase price of $292,790.
Inbound Investments
- Lucid Diagnostics bolstered its cash reserves by approximately $27.0 million through an underwritten public offering of common stock that closed in September 2025.
- In December 2024, the company secured approximately $18 million in net cash proceeds from new convertible debt financing with existing long-term equity shareholders, after repaying existing convertible debt.
Capital Expenditures
- Lucid Diagnostics invested $1.3 million in research and development during the third quarter of 2025.
Latest Trefis Analyses
| Title | Date | |
|---|---|---|
| DASHBOARDS | ||
| Lucid Diagnostics Earnings Notes | 12/16/2025 | |
| With Lucid Diagnostics Stock Surging, Have You Considered The Downside? | 10/17/2025 |
| Title | |
|---|---|
| ARTICLES |
Trade Ideas
Select ideas related to LUCD.
| Date | Ticker | Company | Category | Trade Strategy | 6M Fwd Rtn | 12M Fwd Rtn | 12M Max DD |
|---|---|---|---|---|---|---|---|
| 04302026 | GEHC | GE HealthCare Technologies | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 0.0% | 0.0% | 0.0% |
| 04302026 | IQV | IQVIA | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 0.0% | 0.0% | 0.0% |
| 04302026 | UHS | Universal Health Services | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 0.0% | 0.0% | 0.0% |
| 04302026 | ABT | Abbott Laboratories | Dip Buy | DB | P/E OPMDip Buy with Low PE and High MarginBuying dips for companies with tame PE and meaningfully high operating margin | 0.0% | 0.0% | 0.0% |
| 04302026 | ZBIO | Zenas BioPharma | Insider | Insider Buys 45DStrong Insider BuyingCompanies with multiple insider buys in the last 45 days | 0.0% | 0.0% | 0.0% |
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 20.32 |
| Mkt Cap | 1.0 |
| Rev LTM | 431 |
| Op Inc LTM | -64 |
| FCF LTM | -26 |
| FCF 3Y Avg | -34 |
| CFO LTM | -12 |
| CFO 3Y Avg | -4 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | 10.2% |
| Rev Chg 3Y Avg | 25.1% |
| Rev Chg Q | 14.8% |
| QoQ Delta Rev Chg LTM | 3.5% |
| Op Inc Chg LTM | -3.2% |
| Op Inc Chg 3Y Avg | 5.0% |
| Op Mgn LTM | -22.8% |
| Op Mgn 3Y Avg | -20.6% |
| QoQ Delta Op Mgn LTM | 3.0% |
| CFO/Rev LTM | -7.9% |
| CFO/Rev 3Y Avg | -1.4% |
| FCF/Rev LTM | -12.2% |
| FCF/Rev 3Y Avg | -8.6% |
Valuation
| Median | |
|---|---|
| Name | |
| Mkt Cap | 1.0 |
| P/S | 3.6 |
| P/Op Inc | -9.6 |
| P/EBIT | -8.6 |
| P/E | -9.0 |
| P/CFO | 4.3 |
| Total Yield | -6.0% |
| Dividend Yield | 0.0% |
| FCF Yield 3Y Avg | -4.2% |
| D/E | 0.1 |
| Net D/E | -0.1 |
Returns
| Median | |
|---|---|
| Name | |
| 1M Rtn | -0.0% |
| 3M Rtn | -23.8% |
| 6M Rtn | -8.1% |
| 12M Rtn | 13.5% |
| 3Y Rtn | -6.3% |
| 1M Excs Rtn | -9.4% |
| 3M Excs Rtn | -27.0% |
| 6M Excs Rtn | -11.8% |
| 12M Excs Rtn | -10.2% |
| 3Y Excs Rtn | -79.9% |
Price Behavior
| Market Price | $1.09 | |
| Market Cap ($ Bil) | 0.1 | |
| First Trading Date | 10/14/2021 | |
| Distance from 52W High | -31.4% | |
| 50 Days | 200 Days | |
| DMA Price | $1.27 | $1.16 |
| DMA Trend | indeterminate | down |
| Distance from DMA | -13.9% | -6.3% |
| 3M | 1YR | |
| Volatility | 64.8% | 66.6% |
| Downside Capture | 1.37 | 0.71 |
| Upside Capture | 124.62 | 75.42 |
| Correlation (SPY) | 32.9% | 14.4% |
| 1M | 2M | 3M | 6M | 1Y | 3Y | |
|---|---|---|---|---|---|---|
| Beta | 1.84 | 1.51 | 1.44 | 1.04 | 0.78 | 0.65 |
| Up Beta | 1.19 | 1.24 | 0.98 | 0.13 | 0.31 | 0.33 |
| Down Beta | 10.42 | 0.70 | 0.70 | 0.89 | 0.58 | 0.64 |
| Up Capture | 56% | 68% | 163% | 118% | 68% | 42% |
| Bmk +ve Days | 15 | 22 | 31 | 66 | 141 | 428 |
| Stock +ve Days | 7 | 12 | 23 | 49 | 101 | 329 |
| Down Capture | 1135% | 273% | 193% | 152% | 125% | 101% |
| Bmk -ve Days | 4 | 18 | 30 | 56 | 108 | 321 |
| Stock -ve Days | 10 | 22 | 31 | 57 | 114 | 335 |
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with LUCD | |
|---|---|---|---|---|
| LUCD | -14.7% | 66.6% | 0.03 | - |
| Sector ETF (XLV) | 7.8% | 15.7% | 0.29 | 13.1% |
| Equity (SPY) | 29.7% | 12.5% | 1.83 | 14.5% |
| Gold (GLD) | 39.6% | 27.2% | 1.21 | 7.3% |
| Commodities (DBC) | 50.7% | 18.0% | 2.18 | -4.8% |
| Real Estate (VNQ) | 12.1% | 13.5% | 0.60 | 5.5% |
| Bitcoin (BTCUSD) | -19.0% | 42.2% | -0.39 | 10.0% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with LUCD | |
|---|---|---|---|---|
| LUCD | -37.8% | 67.7% | -0.49 | - |
| Sector ETF (XLV) | 5.1% | 14.6% | 0.17 | 15.3% |
| Equity (SPY) | 12.8% | 17.1% | 0.59 | 21.4% |
| Gold (GLD) | 20.1% | 17.9% | 0.91 | 3.7% |
| Commodities (DBC) | 14.1% | 19.1% | 0.60 | -1.5% |
| Real Estate (VNQ) | 3.3% | 18.8% | 0.08 | 17.2% |
| Bitcoin (BTCUSD) | 7.3% | 56.2% | 0.34 | 12.1% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with LUCD | |
|---|---|---|---|---|
| LUCD | -21.1% | 67.7% | -0.49 | - |
| Sector ETF (XLV) | 9.1% | 16.5% | 0.45 | 15.3% |
| Equity (SPY) | 14.9% | 17.9% | 0.71 | 21.4% |
| Gold (GLD) | 13.4% | 15.9% | 0.70 | 3.7% |
| Commodities (DBC) | 9.7% | 17.7% | 0.46 | -1.5% |
| Real Estate (VNQ) | 5.6% | 20.7% | 0.23 | 17.2% |
| Bitcoin (BTCUSD) | 67.1% | 66.9% | 1.06 | 12.1% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Returns Analyses
Earnings Returns History
Expand for More| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 3/26/2026 | -3.4% | -3.4% | -10.1% |
| 11/12/2025 | 6.7% | 1.0% | 11.5% |
| 8/13/2025 | -1.6% | -0.4% | 7.3% |
| 3/25/2025 | 3.3% | -0.7% | -14.0% |
| 11/13/2024 | 5.0% | -4.4% | -22.6% |
| 8/12/2024 | 6.3% | 5.7% | 1.5% |
| 5/14/2024 | -2.2% | -2.1% | -21.2% |
| 11/14/2023 | 12.1% | 12.1% | 18.1% |
| ... | |||
| SUMMARY STATS | |||
| # Positive | 7 | 4 | 4 |
| # Negative | 5 | 8 | 8 |
| Median Positive | 6.3% | 8.9% | 9.4% |
| Median Negative | -2.2% | -3.9% | -22.1% |
| Max Positive | 12.1% | 12.8% | 18.1% |
| Max Negative | -11.9% | -29.3% | -38.2% |
SEC Filings
Expand for More| Report Date | Filing Date | Filing |
|---|---|---|
| 12/31/2025 | 03/25/2026 | 10-K |
| 09/30/2025 | 11/12/2025 | 10-Q |
| 06/30/2025 | 08/12/2025 | 10-Q |
| 03/31/2025 | 05/13/2025 | 10-Q |
| 12/31/2024 | 03/24/2025 | 10-K |
| 09/30/2024 | 11/12/2024 | 10-Q |
| 06/30/2024 | 08/12/2024 | 10-Q |
| 03/31/2024 | 05/13/2024 | 10-Q |
| 12/31/2023 | 03/25/2024 | 10-K |
| 09/30/2023 | 11/13/2023 | 10-Q |
| 06/30/2023 | 08/14/2023 | 10-Q |
| 03/31/2023 | 05/15/2023 | 10-Q |
| 12/31/2022 | 03/14/2023 | 10-K |
| 09/30/2022 | 11/14/2022 | 10-Q |
| 06/30/2022 | 08/15/2022 | 10-Q |
| 03/31/2022 | 05/16/2022 | 10-Q |
Insider Activity
Expand for More| # | Owner | Title | Holding | Action | Filing Date | Price | Shares | Transacted Value | Value of Held Shares | Form |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Matheis, Dennis | Direct | Buy | 8222025 | 1.02 | 100,000 | 101,840 | 677,687 | Form | |
| 2 | Matheis, Dennis | Direct | Buy | 5222025 | 1.32 | 33,218 | 43,795 | 461,440 | Form | |
| 3 | Matheis, Dennis | Direct | Buy | 5222025 | 1.32 | 129,684 | 171,520 | 418,976 | Form | |
| 4 | Matheis, Dennis | Direct | Buy | 5222025 | 1.29 | 187,098 | 242,292 | 242,292 | Form |
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |
Prefer one of these to Trefis? Tell us why.